Fabry disease

Drugs of Today

Volumn 42, Issue 1, 2006, Pages 65-70

  Levin, Mark ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; CARBAMAZEPINE; CORTICOSTEROID; GABAPENTIN; PHENYTOIN; PLACENTA ENZYME; PREDNISONE; RECOMBINANT ENZYME; RECOMBINANT GALACTOSIDASE A; RECOMBINANT GLUCOSYLCERAMIDE; STEROID; UNCLASSIFIED DRUG;

CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; DISEASE CARRIER; DOSE RESPONSE; ENZYME REPLACEMENT; ENZYME THERAPY; FABRY DISEASE; HUMAN; NAUSEA AND VOMITING; NONHUMAN; PHENOTYPE; REVIEW; RIGOR;

ALPHA-GALACTOSIDASE; ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; FABRY DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS;

EID: 33645084802     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.1.957357     Document Type: Review

References (35)

1. Fabry, J. Beitrag zur Kennthis der Purpura heamorrhagica nodularis. Arch Dermatol Syph 1898, 43: 187.
2. Anderson, W. A case of angio-keratoma. Br J Derm 1898, 10: 13.
3. Sweeley, C.C., Klionsky, B. Fabry disease: Classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biolog Chem 1963, 238: 3148-50.
4. Brady, R.O., Gal, A.E., Bradley, R.M., Martensson, E., Warshaw, A.L., Laaster, L. Enzymatic defect in Fabry's disease. N Engl J Med 1967, 276: 1163.
5. Peters, F.P.J., Sommer, A., Vermeulen, A., Cheriex, E.C., Kho, T.L. Fabry's disease: A multidisciplinary disorder. Postgrad Med J 1997, 73: 710-2.
6. Faraggiana, T., Churg, J., Grishman, E. et al. Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol 1981, 103: 247-62.
7. Maizel, S.E., Simmons, R.L., Kjellstrand, C., Fryd, D.S. Ten-year experience in renal transplantation for Fabry's disease. Transplant Proc 1981, 13: 57-9.
8. Colombi, A., Kostyal, A., Bracher, R. et al. Angiokeratoma corporis diffusum - Fabry's disease. Helv Med Acta 1967, 34: 67-83.
9. Kahn, P. Anderson-Fabry disease: A histopathological study of three cases with observations on the mechanism of production of pain. Neurol Neurosurg Psychiatry 1973, 36: 1053-62.
10. Schiffmann, R., Floeter, M.K., Dambrosia, J.M. et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003, 28: 703-10.
11. Fiedler, L., Ashton-Prolla, P., Eng, C., Babyatsky, M.W. High prevalence of gastrointestinal symptoms in Fabry's disease. Gastroenterology 1998, 114 (4 Part. 2): A369.
12. Grewal, R.P. Stroke in Fabry's disease. J Neurol 1994, 241: 153-6.
13. Morgan, S.H., Rudge, P., Smith, S. et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) - Ivestigation of symptomatic and presymptomatic patients. Q J Med 1990, 75: 491-507.
14. Tsakiris, D. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrology Dialysis Transplantation 1996, 11: 4-20.
15. Brown, L.K., Miller, A., Bhuptani, A. et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 1997, 155: 1004-10.
16. Gemignani, F., Pietrini, Y., Tagliavini, F. et al. Fabry's disease with familial lymphedema of the lower limbs. Eur Neurol 1979, 18: 84.
17. Sachdev, B.T., Takenaka, T., Teraguchi, H. et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circul 2002, 105: 1407-4.
18. Linhart, A., Lubanda, J., Palecek, T. et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001, 24 (Suppl. 2): 75-83.
19. Von Sheidt, W., Eng, C.M., Fitzmaurice, T.F. et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991, 324: 395-9.
20. Nakao, S., Taknaka, T., Maeda, M. et al. An atypical variant of Fabry disease in men with left ventricular hypertrophy. N Engl J Med 1995, 333: 288-93.
21. Nakao, S., Kodama, C., Takenak, Y., Yasumoto, Y. Fabry disease: Detection of undiagnosed hemodialysis patients and indentification of a renal variant phenotype. Kidney Inter 2003, 64: 801-7.
22. Thadhani, R., Wolf, M., West, M.L. et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002, 61: 249-55.
23. Bird, T.D., Lagunoff, D.L. Neurological manifestations of Fabry disease in female carriers. Ann Neurol 1978, 4: 537-40.
24. Rodriguez, F.H. Jr., Hoffmann, E.O., Ordinario, A.T. Jr., Baliga, M. Fabry's disease in a heterozygous woman. Arch Pathol Lab Med 1985, 109: 89-91.
25. Sher, N.A., Letson, R.D., Desnick, R.J. The ocular manifestations in Fabry disease. Arch Ophthalmol 1979, 97: 671-6.
26. Levade, T., Giordano, F., Maret, A., Marguery, M.-C., Bazex, J., Salvayre, R. Different phenotypic expression of Fabry disease in females. J Inherit Metab Dis 1991, 14: 105.
27. Gibas, A., Klatt, R., Johnson, J., Clarke, J., Katz, J. The patients' perspective on pain of Fabry disease. American Pain Society Annual Meeting, Vancouver, Canada, 2004, Poster #724.
28. Ashton-Prolla, P., Tong, B., Shabbeer, J. et al. Fabry disease: Twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 2000, 48: 227-35.
29. Schiffmann, R., Murray, G.J., Treco, D. et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000, 97: 365-37.
30. Ioannou, Y.A., Zeidner, K.M., Gordon, R.E., Desnick, R.J. Fabry disease: Preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001, 68: 14-25.
31. Desnick, R.J., Dean K.J., Grabowski, G.A., Bishop, D.F., Sweeley, C.C. Enzyme therapy in Fabry disease: Differential plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase isozymes. Proc Natl Acad Sci USA 1979, 76: 5326.
32. Eng, C.M., Banikazemi, M., Gordon, R. et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001, 68: 711-22.
33. Schiffmann, R., Kopp, J.B., Austin, H.A. et al. Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA 2001, 285: 2743-9.
34. Desnick, R.J., Brady, R., Barranger, J. et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003, 38: 338-46.
35. Fabrazyme prescribing information.